Recent

% | $
Quotes you view appear here for quick access.

Osiris Therapeutics, Inc. Message Board

  • e failure of Wright Medical Group’s (WMGI) Augment bone graft to get past the FDA was not wholly unexpected in light of its first-time defeat and an almost perfunctory attempt to plug the holes in the data for the resubmission. Nevertheless Wright’s investors appeared to be taken by surprise, sending the company’s shares down 8% on Friday.

    Augment’s denial leaves Medtronic (MDT) and Integra LifeSciences (IART) dominating the market for these contentious products, EvaluateMedTech data show. But with Medtronic’s flagship orthobiologic graft Infuse beset by negative trial findings, its bone filler sales are set to stagnate. Indeed, consensus forecasts show that the companies with the fastest-growing orthobiologic sales are relative minnows in the sector (see table).

 
OSIR
4.99-0.06(-1.19%)Aug 26 4:00 PMEDT